KR102317334B1 - ＮＩＫ 억제제로서의 신규 1-(4-피리미디닐)-1Ｈ-피롤로[3,2-ｃ]피리딘 유도체들 - Google Patents

ＮＩＫ 억제제로서의 신규 1-(4-피리미디닐)-1Ｈ-피롤로[3,2-ｃ]피리딘 유도체들 Download PDF

Info

Publication number
KR102317334B1
KR102317334B1 KR1020167007899A KR20167007899A KR102317334B1 KR 102317334 B1 KR102317334 B1 KR 102317334B1 KR 1020167007899 A KR1020167007899 A KR 1020167007899A KR 20167007899 A KR20167007899 A KR 20167007899A KR 102317334 B1 KR102317334 B1 KR 102317334B1
Authority
KR
South Korea
Prior art keywords
alkyl
hydrogen
group
substituted
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167007899A
Other languages
English (en)
Korean (ko)
Other versions
KR20160058814A (ko
Inventor
조지 하인드
패트리지아 티셀리
데이비드 에드워드 클락
야뉴스 죠제프 쿠라고프스키
칼럼 맥클레오드
사무엘 에드워드 만
테리 아론 판챨
스티븐 콜린 프라이스
존 게리 몬타나
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20160058814A publication Critical patent/KR20160058814A/ko
Application granted granted Critical
Publication of KR102317334B1 publication Critical patent/KR102317334B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020167007899A 2013-09-26 2014-09-25 ＮＩＫ 억제제로서의 신규 1-(4-피리미디닐)-1Ｈ-피롤로[3,2-ｃ]피리딘 유도체들 Expired - Fee Related KR102317334B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13186139 2013-09-26
EP13186139.5 2013-09-26
EP14176121 2014-07-08
EP14176121.3 2014-07-08
PCT/EP2014/070484 WO2015044267A1 (en) 2013-09-26 2014-09-25 NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS

Publications (2)

Publication Number Publication Date
KR20160058814A KR20160058814A (ko) 2016-05-25
KR102317334B1 true KR102317334B1 (ko) 2021-10-26

Family

ID=51619194

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167007899A Expired - Fee Related KR102317334B1 (ko) 2013-09-26 2014-09-25 ＮＩＫ 억제제로서의 신규 1-(4-피리미디닐)-1Ｈ-피롤로[3,2-ｃ]피리딘 유도체들

Country Status (14)

Country Link
US (1) US10005773B2 (https=)
EP (1) EP3071566B1 (https=)
JP (1) JP6402179B2 (https=)
KR (1) KR102317334B1 (https=)
CN (1) CN105579451B (https=)
AU (1) AU2014327233B2 (https=)
BR (1) BR112016005914A2 (https=)
CA (1) CA2922753C (https=)
EA (1) EA029595B1 (https=)
ES (1) ES2804595T3 (https=)
IL (1) IL244706B (https=)
MX (1) MX373186B (https=)
TW (1) TWI704146B (https=)
WO (1) WO2015044267A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI627173B (zh) * 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
AU2015334917B2 (en) 2014-10-23 2019-08-29 Janssen Pharmaceutica Nv New compounds as NIK inhibitors
JP6616412B2 (ja) 2014-10-23 2019-12-04 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としての新規のピラゾロピリミジン誘導体
MX371151B (es) 2014-10-23 2020-01-20 Janssen Pharmaceutica Nv NUEVOS DERIVADOS DE TIENOPIRIMIDINA EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).
BR112017008039B1 (pt) 2014-10-23 2023-04-11 Janssen Pharmaceutica N.V. Derivados de pirazol como inibidores de nik, seu uso no tratamento ou prevenção de câncer e composição farmacêutica que os compreende
EP3405464B1 (en) * 2016-01-22 2019-12-04 Janssen Pharmaceutica NV New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
ES2775449T3 (es) 2016-01-22 2020-07-27 Janssen Pharmaceutica Nv Nuevos derivados de cianoindolina sustituida como inhibidores de nik
ES2837157T3 (es) 2016-06-30 2021-06-29 Janssen Pharmaceutica Nv Derivados de cianoindolina como inhibidores de NIK
WO2018002217A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Heteroaromatic derivatives as nik inhibitors
WO2018037059A1 (en) * 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
WO2018037058A1 (en) 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
CN114222737B (zh) 2019-05-31 2024-07-26 詹森药业有限公司 NF-κB诱导激酶的小分子抑制剂
CN113816957B (zh) * 2021-10-29 2023-04-07 浙江工业大学 4-(7-氮杂吲哚)-2-氨基嘧啶类化合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058850A2 (en) 2005-11-10 2007-05-24 Smithkline Beecham Corporation Inhibitors of akt activity
WO2009158011A1 (en) 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
US20120214762A1 (en) 2011-03-16 2012-08-23 Genentech, Inc. 6,5-heterocyclic propargylic alcohol compounds and uses therefor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3990061B2 (ja) * 1998-01-05 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤
WO2005103003A2 (en) 2004-04-26 2005-11-03 Pfizer Inc. Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
CN102143746A (zh) 2008-07-03 2011-08-03 埃克塞利希斯股份有限公司 Cdk 调节剂
WO2010042337A1 (en) 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
WO2011050245A1 (en) * 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
TWI663166B (zh) * 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
BR112017008039B1 (pt) 2014-10-23 2023-04-11 Janssen Pharmaceutica N.V. Derivados de pirazol como inibidores de nik, seu uso no tratamento ou prevenção de câncer e composição farmacêutica que os compreende
AU2015334917B2 (en) 2014-10-23 2019-08-29 Janssen Pharmaceutica Nv New compounds as NIK inhibitors
MX371151B (es) 2014-10-23 2020-01-20 Janssen Pharmaceutica Nv NUEVOS DERIVADOS DE TIENOPIRIMIDINA EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).
JP6616412B2 (ja) 2014-10-23 2019-12-04 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としての新規のピラゾロピリミジン誘導体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058850A2 (en) 2005-11-10 2007-05-24 Smithkline Beecham Corporation Inhibitors of akt activity
WO2009158011A1 (en) 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
US20120214762A1 (en) 2011-03-16 2012-08-23 Genentech, Inc. 6,5-heterocyclic propargylic alcohol compounds and uses therefor

Also Published As

Publication number Publication date
IL244706B (en) 2021-02-28
ES2804595T3 (es) 2021-02-08
WO2015044267A1 (en) 2015-04-02
JP2016531868A (ja) 2016-10-13
KR20160058814A (ko) 2016-05-25
TWI704146B (zh) 2020-09-11
CN105579451A (zh) 2016-05-11
MX373186B (es) 2020-05-12
EA201690645A1 (ru) 2016-08-31
IL244706A0 (en) 2016-04-21
CN105579451B (zh) 2017-10-27
JP6402179B2 (ja) 2018-10-10
EA029595B1 (ru) 2018-04-30
EP3071566B1 (en) 2020-04-15
MX2016003861A (es) 2016-07-26
CA2922753A1 (en) 2015-04-02
BR112016005914A2 (pt) 2017-08-01
EP3071566A1 (en) 2016-09-28
US20160257679A1 (en) 2016-09-08
CA2922753C (en) 2021-08-17
HK1224295A1 (zh) 2017-08-18
US10005773B2 (en) 2018-06-26
TW201602104A (zh) 2016-01-16
AU2014327233B2 (en) 2018-03-01
AU2014327233A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
KR102317334B1 (ko) ＮＩＫ 억제제로서의 신규 1-(4-피리미디닐)-1Ｈ-피롤로[3,2-ｃ]피리딘 유도체들
KR102317335B1 (ko) ＮＩＫ 억제제로서의 신규 3-(1Ｈ-피라졸-4-일)-1Ｈ-피롤로[2,3-ｃ]피리딘 유도체
KR102336291B1 (ko) 암을 치료하기 위한 ＮＩＫ 억제제로서의 3-(2-아미노피리미딘-4-일)-5-(3-하이드록시프로피닐)-1Ｈ-피롤로[2,3-ｃ]피리딘 유도체
KR102524622B1 (ko) Ｎｉｋ 억제제로서의 신규 티에노피리미딘 유도체
KR102500071B1 (ko) Ｎｉｋ 억제제로서의 신규 화합물
KR102523405B1 (ko) Ｎｉｋ 억제제로서의 신규 피라졸로피리미딘 유도체
KR102499862B1 (ko) Ｎｉｋ 억제제로서의 신규 피라졸 유도체
HK1224295B (en) New 1-(4-pyrimidinyl)-1 h-pyrrolo(3,2-c) pyridine derivatives as nik inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20241021

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20241021

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20241021